Kevin Skol

Kevin Skol leads business development activities at Isis Pharmaceuticals.  Kevin is primarily responsible for implementing Isis’ innovative partnering structures which includes traditional licensing transactions, preferred partner alliances and satellite company partnerships.  Prior to Isis, Kevin was a marketing director, neuroscience at Valeant Pharmaceuticals leading its migraine franchise.  Kevin also spent several years in business development at Valeant where the team completed numerous transactions including company and product acquisitions, co-promotions, in-licenses, out-license and divestitures.  Prior to joining Valeant, Kevin was Vice President of Corporate Development at Digital Gene Technologies (DGT), a private genomics based company, who oversaw the Corporate Development and Investor Relations teams.  Prior to DGT, Kevin served in the business development group at Elan where he specialized in drug development and delivery joint ventures between Elan and a range of biotechnology companies.  Prior to Elan, Kevin spent a number of years at Goldman, Sachs & Company as a financial analyst within the Structured Finance and Real Estate Groups.  Kevin serves as a member of the Board of Directors of Ingredient Innovations International (3i), a nutraceuticals company based in Ohio.  Kevin holds a BA in Economics from Yale University and an MBA from the Harvard Business School.